# A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Source: https://onco.cc/trials/nct04094610/  
OnCo record `nct04094610` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Repotrectinib in non-Hodgkin lymphoma and brain and spinal cord tumours, run by Turning Point Therapeutics, Inc., now recruiting.

## Summary

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations is a phase 1/2 interventional study registered as NCT04094610 by Turning Point Therapeutics, Inc., with 75 participants planned, started 2020-03-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Oral repotrectinib (TPX-0005).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04094610
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
- Sponsor: Turning Point Therapeutics, Inc.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT04094610: https://clinicaltrials.gov/study/NCT04094610

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Repotrectinib](https://onco.cc/drugs/repotrectinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04094610.json